| [1] |
Bray GA. Harvey cushing and the neuroendocrinology of obesity[J]. Obes Res, 1994, 2(5): 482-485.
|
| [2] |
Ragnarsson O, Olsson DS, Chantzichristos D, et al. The incidence of Cushing’s disease: a nationwide Swedish study[J]. Pituitary, 2019, 22(2): 179-186.
|
| [3] |
Goodman RL. Diagnosis and differential diagnosis of Cushing’s syndrome[J]. N Engl J Med, 2017, 377(2): e3.
|
| [4] |
Pertichetti M, Serioli S, Belotti F, et al. Pituitary adenomas and neuropsychological status: a systematic literature review[J]. Neurosurg Rev, 2020, 43(4): 1065-1078.
|
| [5] |
Sahu JK, Vaddi VK, Negi S. Review of west syndrome: concerns on optimum dose of adrenocorticotrophic hormone[J]. Clin Drug Investig, 2018, 38(6): 563-564.
|
| [6] |
Ballmann C, Thiel A, Korah HE, et al. USP8 mutations in pituitary cushing adenomas-targeted analysis by next-generation sequencing[J]. J Endocr Soc, 2018, 2(3): 266-278.
|
| [7] |
Faucz FR, Tirosh A, Tatsi C, et al. Somatic USP8 gene mutations are a common cause of pediatric Cushing disease[J]. J Clin Endocrinol Metab, 2017, 102(8): 2836-2843.
|
| [8] |
Sbiera S, Kunz M, Weigand I, et al. The new genetic landscape of Cushing’s disease: deubiquitinases in the spotlight[J]. Cancers (Basel), 2019, 11(11): 1176.
|
| [9] |
Pérez-Rivas LG, Theodoropoulou M, Puar TH, et al. Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson’s tumor[J]. Eur J Endocrinol, 2018, 178(1): 57-63.
|
| [10] |
Perez-Rivas LG, Oβwald A, Knosel T, et al. Expression and mutational status of USP8 in tumors causing ectopic ACTH secretion syndrome[J]. Endocr Relat Cancer, 2017, 24(9): L73-L77.
|
| [11] |
Sesta A, Cassarino MF, Terreni M, et al. Ubiquitin-specific protease 8 mutant corticotrope adenomas present unique secretory and molecular features and shed light on the role of ubiquitylation on ACTH processing[J]. Neuroendocrinology, 2020, 110(1-2): 119-129.
|
| [12] |
Albani A, Theodoropoulou M, Reincke M. Genetics of Cushing’s disease[J]. Clin Endocrinol (Oxf), 2018, 88(1): 3-12.
|
| [13] |
Lin SJ, Yang DR, Yang G, et al. TR2 and TR4 orphan nuclear receptors: an overview[J]. Curr Top Dev Biol, 2017, 125: 357-373.
|
| [14] |
Albani A, Perez-Rivas LG, Reincke M, et al. Pathogenesis of Cushing disease: an update on the genetics of corticotropinomas[J]. Endocr Pract, 2018, 24(10): 907-914.
|
| [15] |
Bergna C, Marin GH, Maiz M, et al. New forms of induction of apoptosis in aggressive lymphoma using peptides that interrupt the RAS/RAF interaction[J]. Ceylon Med J, 2019, 64(2): 46-51.
|
| [16] |
Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M. Medical management of Cushing’s syndrome: current and emerging treatments[J]. Drugs, 2019, 79(9): 935-956.
|
| [17] |
Sakakibara K, Tsujioka T, Kida JI, et al. Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway[J]. Int J Hematol, 2019, 110(2): 213-227.
|
| [18] |
Zhang D, Bergsneider M, Wang MB, et al. Targeting the ERK pathway for the treatment of Cushing’s disease[J]. Oncotarget, 2016, 7(43): 69149-69158.
|
| [19] |
Casals G, Hanzu FA. Cortisol measurements in Cushing’s syndrome: immunoassay or mass spectrometry?[J]. Ann Lab Med, 2020, 40(4): 285-296.
|
| [20] |
Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome[J]. N Engl J Med, 1991, 325(13): 897-905.
|
| [21] |
Wang H, Hou B, Lu L, et al. PET/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study[J]. J Nucl Med, 2018, 59(3): 523-528.
|
| [22] |
Melmed S. Pituitary-tumor endocrinopathies[J]. N Engl J Med, 2020, 382(10): 937-950.
|
| [23] |
Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2017, 102(3): 709-757.
|
| [24] |
Post KD, Pain M, Zarzour H, et al. Transsphenoidal surgery for Cushing’s disease//Laws E Jr, Cohen-Gadol A, Schwartz T, et al. Transsphenoidal Surgery[M]. Berlin: Springer, Cham, 2017: 427-439.
|
| [25] |
Mehta GU, Ding D, Patibandla MR, et al. Stereotactic radiosurgery for Cushing disease: results of an international, multicenter study[J]. J Clin Endocrinol Metab, 2017, 102(11): 4284-4291.
|
| [26] |
Feelders RA, Newell-Price J, Pivonello R, et al. Advances in the medical treatment of Cushing’s syndrome[J]. Lancet Diabetes Endocrinol, 2019, 7(4): 300-312.
|
| [27] |
Nishioka H, Yamada S. Cushing’s disease[J]. J Clin Med, 2019, 8(11): 1951.
|
| [28] |
Belokovskaya R, Ravikumar A, Arumugam D, et al. Mifepristone treatment for mild autonomous cortisol secretion due to adrenal adenomas: a pilot study[J]. Endocr Pract, 2019, 25(8): 846-853.
|
| [29] |
Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 17-26.
|
| [30] |
Tritos NA, Biller BMK. Current management of Cushing’s disease[J]. J Intern Med, 2019, 286(5): 526-541.
|